As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

  5/6/24  Celldex Therapeutics, Inc.        10-Q        3/31/24   60:5M                                     Toppan Merrill/FA2       
  5/6/24  Celldex Therapeutics, Inc.        8-K:2,9      5/6/24   12:254K                                   Globenewswire Inc./FA    
 4/25/24  Celldex Therapeutics, Inc.        ARS        12/31/23    1:2.4M                                   Toppan Merrill/FA        
 4/25/24  Celldex Therapeutics, Inc.        DEF 14A     6/13/24   11:3.3M                                   Toppan Merrill/FA        
  3/1/24  Celldex Therapeutics, Inc.        8-K:1,8,9   2/28/24   14:602K                                   Toppan Merrill/FA        
  3/1/24  Celldex Therapeutics, Inc.        424B5                  2:415K                                   Toppan Merrill/FA        
 2/28/24  Celldex Therapeutics, Inc.        424B5                  1:377K                                   Toppan Merrill/FA        
 2/26/24  Celldex Therapeutics, Inc.        424B5                  2:352K                                   Toppan Merrill/FA        
 2/26/24  Celldex Therapeutics, Inc.        10-K       12/31/23   87:8.5M                                   Toppan Merrill/FA2       
 2/26/24  Celldex Therapeutics, Inc.        8-K:2,9     2/26/24   12:277K                                   Globenewswire Inc./FA    
 2/15/24  Jimenez Freddy A.                 4          Officer²    1:9K   Celldex Therapeutics, Inc.        SEC Connect              
 2/14/24  Point72 Asset Management, L.P.    SC 13G/A               1:64K  Celldex Therapeutics, Inc.        Schulte Roth & Z… LLP/FA 
 2/14/24  Kynam Capital Management, LP      SC 13G                 1:28K  Celldex Therapeutics, Inc.        Adv Consultant Netw… Inc 
 2/14/24  Eventide Asset Management, LLC    SC 13G                 1:54K  Celldex Therapeutics, Inc.        Blu Giant, LLC/FA        
          Finny Kuruvilla, M.D. Ph. D.³
          Robin C. John³
 2/14/24  RTW Investments, LP               SC 13G/A               1:61K  Celldex Therapeutics, Inc.        Schulte Roth & Z… LLP/FA 
 2/13/24  Vanguard Group Inc.               SC 13G/A               1:13K  Celldex Therapeutics, Inc.        Toppan Merrill/FA        
 2/13/24  Polar Capital Holdings plc        SC 13G                 1:85K  Celldex Therapeutics, Inc.        Adviser Compliance … LLC 
  2/9/24  FMR LLC                           SC 13G/A               1:9K   Celldex Therapeutics, Inc.                                 
  2/8/24  Wellington Management Group LLP   SC 13G/A               1:28K  Celldex Therapeutics, Inc.                                 
 1/26/24  BlackRock Inc.                    SC 13G/A               1:14K  Celldex Therapeutics, Inc.        Blackrock Advisors LLC   

____________
¹	Filing/Form Types:
	4	Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 { The Filer is an Insider² of the Issuer }.
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	10-K	Annual Report — Form 10-K.
	10-Q	Quarterly Report — Form 10-Q.
	424B5	Prospectus – Primary Offering or Shelf Securities – New Facts or Events.
	ARS	Annual Report to Security Holders.
	DEF 14A	Definitive Proxy Statement — Schedule 14A.
	SC 13G	Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G.
	/A	Amendment to, or Amended version of, a previous Filing of this Type.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.